JMSB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JMSB presents a strong value opportunity, trading significantly below both its Graham Number ($25.09) and estimated Intrinsic Value ($43.95). While the Piotroski F-Score of 4/9 indicates stable but not exceptional financial health, the company demonstrates robust growth with earnings increasing 26.3% YoY. The valuation is attractive with a P/E of 13.93 and a low Price/Book of 1.11. Despite a heavily bearish technical trend (10/100), the fundamental divergence suggests a potential buying opportunity for long-term investors.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
JMSB vs JPM: Head-to-Head Comparison
This page compares John Marshall Bancorp, Inc. (JMSB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.